Dixon, Lorraine (2010) What is the real cost of bevacizumab for patients with advanced bowel cancer? International Journal of Palliative Nursing, 16 (12). p. 577. ISSN 1357-6321Full text not available from this repository.
The author comments on the decision of the National Institute for Health and Clinical Excellence (NICE) of Great Britain not to support the use of bevacizumab for patients with advanced bowel cancer despite evidence indicating that the drug would grant patients with advanced cancer additional weeks of life compared with chemotherapy alone. The author relates the cost of bevacizumab per patient and why NICE found that bevacizumab therapy failed to demonstrate clinical cost effectiveness. She emphasizes the value of palliative care for cancer patients.
|Uncontrolled Keywords:||Bowel cancer, drug therapy; bowel cancer, biological therapy|
|Subjects:||R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RM Therapeutics. Pharmacology
|Divisions:||Schools and Research Institutes > School of Health and Social Care > Health and Social Care|
|Research Priority Areas:||Learning and Professional Contexts|
|Depositing User:||Susan Turner|
|Date Deposited:||18 Feb 2015 15:49|
|Last Modified:||26 Oct 2015 13:03|